Evexia Lifecare Acquires Major Stake in Regenerative Medicine Pioneer Diponed Bio

Evexia Lifecare Limited is set to acquire a 65% stake in Diponed Bio Private Limited, marking a significant move in the biotech sector. The acquisition aims to enhance Evexia's presence in regenerative medicine, with substantial funding to accelerate Diponed Bio's research and development capabilities in advanced biological products.

In a bold stride within the biotechnology and healthcare sectors, Evexia Lifecare Limited has announced its intent to acquire a controlling 65% stake in Diponed Bio Private Limited, a renowned figure in regenerative medicine. The companies signed a term sheet on November 8, 2024, detailing Evexia's strategic acquisition plan.

As part of the acquisition, Evexia will purchase 18,600 fresh equity shares at Rs. 10 each, securing a majority hold in Diponed Bio. Additionally, Evexia will inject INR 200 million in funding to fuel Diponed Bio's business expansion, bolstering its innovative solutions in tissue engineering and chronic disease therapy.

This acquisition not only expands Evexia's footprint in the rapidly growing biotech industry but also accelerates Diponed Bio's research and development efforts. The collaboration aims to make cutting-edge, affordable treatments accessible, addressing significant healthcare challenges worldwide.

(With inputs from agencies.)